Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 584-587

  Tashiro, Masato ^a   Izumikawa, Koichi ^a   Minematsu, Asuka ^a   Hirano, Katsuji ^a   Iwanaga, Naoki ^a   Ide, Shotaro ^a   Mihara, Tomo ^a   Hosogaya, Naoki ^a,c   Takazono, Takahiro ^a   Morinaga, Yoshitomo ^b   Nakamura, Shigeki ^a   Kurihara, Shintaro ^b   Imamura, Yoshifumi ^a   Miyazaki, Taiga ^a   Nishino, Tomoya ^a   Tsukamoto, Misuzu ^b   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Yanagihara, Katsunori ^b   Yasuoka, Akira ^b   Tashiro, Takayoshi ^a   Kohno, Shigeru ^a   more..

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; TRIAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; FUNGAL STRAIN; FUNGUS ISOLATION; GENE MUTATION; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

AMINO ACID SUBSTITUTION; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FUNGAL PROTEINS; HUMANS; ITRACONAZOLE; JAPAN; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; PYRIMIDINES; SEQUENCE ANALYSIS, DNA; TRIAZOLES;

EID: 84455170016     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05394-11     Document Type: Article

References (38)

1. Alanio A, et al. 2011. Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies. J. Antimicrob. Chemother. 66:371-374.
2. Alcazar-Fuoli L, Mellado E, Cuenca-Estrella M, Sanglard D. 2011. Probing the role of point mutations in the cyp51A gene from Aspergillus fumigatus in the model yeast Saccharomyces cerevisiae. Med. Mycol. 49: 276-284.
3. Arabatzis M, et al. 2011. Polyphasic identification and susceptibility to seven antifungals of 102 Aspergillus isolates recovered from immunocompromised hosts in Greece. Antimicrob. Agents Chemother. 55:3025-3030.
4. Arendrup MC, et al. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080.
5. Bellete B, et al. 2010. Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med. Mycol. 48:197-200.
6. Bueid A, et al. 2010. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J. Antimicrob. Chemother. 65:2116-2118.
7. Clinical Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Approved standard M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Rodriguez-Tudela JL. 2003. A point mutation in the 14α-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:1120-1124.
9. Espinel-Ingroff A, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). J. Clin. Microbiol. 48:3251-3257.
10. Espinel-Ingroff A, et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:2855-2859.
11. Hinrikson HP, Hurst SF, Lott TJ, Warnock DW, Morrison CJ. 2005. Assessment of ribosomal large-subunit D1-D2, internal transcribed spacer 1, and internal transcribed spacer 2 regions as targets for molecular identification of medically important Aspergillus species. J. Clin. Microbiol. 43:2092-2103. (Pubitemid 40656213)
12. Howard SJ, et al. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
13. Izumikawa K, Takazono T, Kohno S. 2010. Chronic Aspergillus infections of the respiratory tract: diagnosis, management and antifungal resistance. Curr. Opin. Infect. Dis. 23:584-589.
14. Kohno S, Izumikawa K. 2010. Posaconazole for chronic pulmonary aspergillosis: The next strategy against the threat of azole resistant Aspergillus infection. Clin. Infect. Dis. 51:1392-1394.
15. Kohno S, et al. 2010. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J. Infect. 61:410-418.
16. Kume H, et al. 2011. Epidemiology of visceral mycoses in autopsy cases in Japan: comparison of the data from 1989, 1993, 1997, 2001, 2005 and 2007 in annual of pathological autopsy cases in Japan. Med. Mycol. J. 52:117-127.
17. Lockhart SR, et al. 2011. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrob. Agents Chemother. 55: 4465-4468.
18. Lockhart SR, et al. 2011. In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network. Antimicrob. Agents Chemother. 55:3944-3946.
19. Mann PA, et al. 2003. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14α-demethylase. Antimicrob. Agents Chemother. 47:577-581. (Pubitemid 36158085)
20. Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, Rodriguez-Tudela JL. 2001. Identification of two different 14-α sterol demethylase-related genes (cyp51A and cyp51B) inAspergillus fumigatus and other Aspergillus species. J. Clin. Microbiol. 39:2431-2438. (Pubitemid 32606215)
21. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. 2004. Substitutions at methionine 220 in the 14α- sterol demethylase (CYP51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750. (Pubitemid 38823458)
22. Mellado E, et al. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51: 1897-1904. (Pubitemid 46903071)
23. Mortensen KL, et al. 2011. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility. Eur. J. Clin. Microbiol. Infect. Dis. 40:1355-1363.
24. Mortensen KL, et al. 2010. Environmental study of azole-resistant Aspergillus fumigatus and other Aspergilli in Austria, Denmark, and Spain. Antimicrob. Agents Chemother. 54:4545-4549.
25. Pfaller M, et al. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J. Clin. Microbiol. 49:586-590.
26. Pfaller MA, et al. 2010. Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods. Diagn. Microbiol. Infect. Dis. 67:56-60.
27. Pfaller MA, et al. 2008. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species. J. Clin. Microbiol. 46:2568-2572.
28. Rajendran R, et al. 2011. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob. Agents Chemother. 55:2092-2097.
29. Rodriguez-Tudela JL, et al. 2008. Epidemiological cutoffs and crossresistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472. (Pubitemid 351915677)
30. Slaven JW, et al. 2002. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet. Biol. 36:199-206.
31. Snelders E, et al. 2009. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl. Environ. Microbiol. 75: 4053-4057.
32. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJG. 2010. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob. Agents Chemother. 54:2425-2430.
33. Snelders E, et al. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219.
34. Tashiro T, et al. 2011. Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward. Med. Mycol. 49:581-587.
35. Thors VS, Bierings MB, Melchers WJ, Verweij PE, Wolfs TF. 2011. Pulmonary aspergillosis caused by a pan-azole-resistant Aspergillus fumigatus in a 10-year-old boy. Pediatr. Infect. Dis. J. 30:268-270.
36. Verweij PE, Howard SJ, Melchers WJG, Denning DW. 2009. Azoleresistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resistance Updates 12:141-147.
37. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46: 327-360. (Pubitemid 351265310)
38. Xiao L, et al. 2004. Three-dimensional models of wild-type and mutated Forms of Cytochrome P450 14α-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother. 48:568-574. (Pubitemid 38141718)